NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 5.6% – Here’s Why

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shares were down 5.6% during trading on Monday . The stock traded as low as $30.06 and last traded at $29.9130. Approximately 698,804 shares changed hands during trading, a decline of 31% from the average session volume of 1,019,825 shares. The stock had previously closed at $31.68.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday. BMO Capital Markets began coverage on NewAmsterdam Pharma in a research note on Monday. They set an “outperform” rating and a $58.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Royal Bank Of Canada lifted their price objective on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.42.

NewAmsterdam Pharma Price Performance

The stock has a market cap of $3.69 billion, a price-to-earnings ratio of -17.61 and a beta of 0.08. The stock’s 50-day moving average is $33.17 and its 200 day moving average is $32.95.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million during the quarter. Analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 40,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $30.20, for a total value of $1,208,000.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $735,460.60. The trade was a 62.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 12.74% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NAMS. Bank of America Corp DE lifted its holdings in NewAmsterdam Pharma by 84.4% in the first quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after acquiring an additional 387,698 shares during the period. Stempoint Capital LP grew its stake in shares of NewAmsterdam Pharma by 147.1% during the 1st quarter. Stempoint Capital LP now owns 180,658 shares of the company’s stock worth $5,783,000 after purchasing an additional 107,552 shares during the period. California State Teachers Retirement System grew its stake in shares of NewAmsterdam Pharma by 34.9% during the 1st quarter. California State Teachers Retirement System now owns 54,329 shares of the company’s stock worth $1,739,000 after purchasing an additional 14,053 shares during the period. Maverick Capital Ltd. increased its holdings in shares of NewAmsterdam Pharma by 15.4% in the 1st quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock valued at $69,987,000 after purchasing an additional 292,176 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in shares of NewAmsterdam Pharma by 35.6% in the 1st quarter. Sei Investments Co. now owns 55,637 shares of the company’s stock valued at $1,781,000 after purchasing an additional 14,597 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.